CTRI/2022/04/042091进行中（未招募）1 期
An open label safety and efficacy study of a polyherbal local anaesthetic parenteral formulation by estimating pharmacokinetic parameters in healthy adults
Pankajakasthuri Herbals India Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Healthy volunteers
- •Has a legally acceptable representative capable of under standing the informed consent documents and providing consent on the participants behalf
- •Normal laboratory values in CBC, LFT and RFT
- •Non smokers, non substance abusers, non alcoholic
排除标准
- •1.Pregnant or breastfeeding women.
- •2.Body mass index superior to 35ââ?¬â?°kg/m2.
- •3.Allergy to any one of the ingredients in the formulation.
- •4.Uncontrolled hypertension/congenital heart problems.
- •5.Life-threatening comorbidities.
- •6.Adults legally protected (under judicial protection, guardianship or supervision) and persons deprived of their liberty.
- •7.Those who are taking regular medication
- •8.Any other chronic illness
研究者
相似试验
进行中（未招募）
1 期
A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders (UCDs)EUCTR2016-003460-38-Outside-EU/EEAHorizon Therapeutics, LLC24
进行中（未招募）
1 期
To study the safety and efficacy of adult stem cell therapy in treating end stage lung diseasesCTRI/2015/02/005569Global Hospiatls50
进行中（未招募）
不适用
An Efficacy and 2-year Safety Study of Rosuvastatin in Children and Adolescents (aged from 6 to less than 18 years) with Familial (inherited) Hypercholesterolaemia (high level of cholesterol in blood)EUCTR2009-016492-29-Outside-EU/EEAAstraZeneca AB200
进行中（未招募）
1 期
An Efficacy and 2-Year Safety Study of Open-label Rosuvastatin in Children and Adolescents (aged from 6 to less than 18 years) with Familial HypercholesterolaemiaMale and female children and adolescents (aged 6 to < 18 years) with FH* and at least 1 of the following criteria: 1. Fasting LDL-C>190 mg/dL (4.92 mmol/L) at baseline OR 2. Fasting LDL-C >160 mg/dL (4.10 mmol/L) at baseline in combination with evidence of other risk factors. *Familial hypercholesterolaemia is defined by a documented genetic defect in LDL receptor or Apo B or documented evidence of familial hypercholesterolaemia in a first-degree relative.EUCTR2009-016492-29-BEAstraZeneca AB200
进行中（未招募）
不适用
An Efficacy and 2-Year Safety Study of Rosuvastatin in Children and Adolescents (aged from 6 to less than 18 years) with Familial Hypercholesterolaemia (high level of cholesterol in blood, which presented in a few relatives in one family)Male and female children and adolescents (aged 6 to < 18 years) with FH* and at least 1 of the following criteria: 1. Fasting LDL-C>190 mg/dL (4.92 mmol/L) at baseline OR 2. Fasting LDL-C >160 mg/dL (4.10 mmol/L) at baseline in combination with evidence of other risk factors. *Familial hypercholesterolaemia is defined by a documented genetic defect in LDL receptor or Apo B or documented evidence of familial hypercholesterolaemia in a first-degree relative.EUCTR2009-016492-29-NLAstraZeneca AB200